RA CAPITAL MANAGEMENT, L.P.
10% Owner; Director; Director, 10% Owner · 19 filings · Latest: Jul 29, 2026
Acrivon Therapeutics, Inc.
Acumen Pharmaceuticals, Inc.
Artiva Biotherapeutics, Inc.
Bicara Therapeutics Inc.
Climb Bio, Inc.
Hemab Therapeutics Holdings, Inc.
Inhibikase Therapeutics, Inc.
Nkarta, Inc.
Parabilis Medicines, Inc.
Tyra Biosciences, Inc.
Werewolf Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
COAG | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | May 8, 2026 | Purchase | $24.98 | 1,483 | $37.0K | 6,325,914 | |
COAG | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | May 7, 2026 | Purchase | $24.46 | 9,906 | $242.3K | 6,324,431 | |
COAG | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | May 6, 2026 | Purchase | $24.60 | 68,018 | $1.7M | 6,314,525 | |
COAG | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | May 5, 2026 | Purchase | $24.63 | 97,411 | $2.4M | 6,246,507 | |
COAG | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | May 4, 2026 | Purchase | $18.00 | 2,675,000 | $48.1M | 354,938 |
← Previous
Page 2 of 2